Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages.
Hemanth K PotluriTun Lee NgMichael A NewtonJin ZhangChristopher A MaherPeter S NelsonDouglas G McNeelPublished in: Journal for immunotherapy of cancer (2021)
This study represents the largest survey of prostate cancer-associated antibodies to date. We have been able to characterize the classes of proteins recognized by patients and determine how they change with disease burden. Our findings further demonstrate the potential of this platform for measuring antigen spread and studying responses to immunomodulatory therapies.